Future Star Laboratories
Programmable biological testing platforms
  1. Now
  2. Next
  3. Later

Future StarLaboratories

We build programmable biological testing platforms for Physical AI laboratories: assays that software can set up, run, measure and analyse. We are starting with bacteria.

DemonstratedIn developmentPlanned
Company
Legal entity
Future Star Labs LLC
Based in
Dallas–Fort Worth
First product
BacteSign
01 · The problem

Biology is still hard to automate.

  • 01The problem

    Manual handling

    Biological experiments depend on hands-on sample preparation that is slow and hard to standardise.

  • 02The problem

    Reproducibility

    Results shift between operators, runs and labs, so the same test can give different answers.

  • 03The problem

    Cost and training

    Consumables are expensive, and every assay takes skilled staff time to learn and run well.

  • 04The problem

    Machines are learning the bench

    AI-driven robots are learning to pipette, handle samples and run experiments. They need assays built for machines: consistent, measurable and controlled by software. Future Star Laboratories builds its assays that way from the start.

02 · Our approach

Engineer the assay itself.

Instead of bolting robots onto existing lab equipment, we design the assay so it can be automated from the start. We control where cells sit and what they are exposed to, then connect that to sensing and software.

SOFTWARE · AI LAB01 · ENGINEERED SURFACES02 · MINIATURISED FLUIDICS03 · IMPEDANCE SENSING04 · AUTOMATED WORKFLOWS05 · PHYSICAL AI INTEGRATIONCELLS
Fig. 01 · From engineered surface to softwareStep 01 of 05
03 · Roadmap

From bacteria to human cells.

  1. Now

    BacteSign for research use

    Bring fluid handling, sensing, instrument control and software together into one system for research-use evaluation.

    In development
  2. Next

    AI-lab integration and external validation

    Connect BacteSign to AI-driven lab automation end to end, and have it tested outside our own lab.

    Planned
  3. Later

    Mammalian-cell applications

    Toxicity and efficacy screening for therapeutics, organoid growth monitoring, and blood-brain barrier models for neurological drug testing. Each needs its own biological validation; bacterial results don't carry over.

    Planned
04 · Team

The founders.

  • Co-founder · Technical lead

    Andre Childs

    PhD in Materials Science and Engineering, University of Central Florida (2024). Research in biosensors, microfabricated assays, bacterial identification and antibiotic susceptibility testing. Leads assay engineering, microfabrication, sensor development and prototyping.

  • Co-founder · Clinical research

    Karolina Budzen

    Brings clinical research expertise, identifies the biomedical use cases where better testing matters most, and shapes product development.

ProgramsAlloy Futures Biotech Startup Academy, Dallas, 2026NSF I-Corps Southeast Regional, Georgia Tech
Our first product

BacteSign